Print

Aspirin Use Appears Linked With Improved Survival After Colon Cancer Diagnosis

EMBARGOED FOR RELEASE: 3 P.M. (CT), MONDAY, MARCH 31, 2014

Media Advisory: To contact corresponding author Gerrit Jan Liefers, M.D., email g.j.liefers@lumc.nl. To contact commentary author Alfred I. Neugut, M.D., Ph.D., call Karin Eskenazi 212-342-0508 or email ket2116@cumc.columbia.edu.

 

JAMA Internal Medicine

 

Bottom Line: Taking low doses of aspirin (which inhibits platelet function) after a colon cancer diagnosis appears to be associated with better survival if the tumor cells express HLA class I antigen.

 

Author: Marlies S. Reimers, M.D., Leiden University Medical Center, the Netherlands, and colleagues.

 

Background: Prior research has suggested aspirin use after a colorectal cancer diagnosis might improve survival.  Although the precise mechanism of aspirin’s anti-cancer effect is unknown, previous data suggest that aspirin may prevent distant metastasis in colorectal cancer.

 

How the Study Was Conducted: The study examined tissue from tumors from 999 patients with colon cancer who underwent surgery between 2002 and 2008. Tissue samples were examined for HLA class I antigen and prostaglandin endoperoxide synthase 2 (PTGS2). Most patients had colon cancer diagnosed at stage III or lower. Data on aspirin use (defined as patients given a prescription for aspirin for 14 days or more after colon cancer diagnosis) came from a prescription database.

 

Results: Of the 999 patients, 182 (18.2 percent) were aspirin users and among them there were 69 deaths (37.9 percent). There were 396 deaths among 817 nonusers of aspirin (48.5 percent). Aspirin use after colon cancer diagnosis was associated with improved overall survival compared with nonuse.  The potential survival benefit of aspirin was strongest among patients with HLA I antigen expression.

The molecular reasons underlying the effects of aspirin are not completely understood, but the authors suggest the results are likely the effect of aspirin on circulating tumor cells and their ability to develop into metastatic deposits.

 

Discussion: “We found that the survival benefit associated with low-dose aspirin use after a diagnosis of colon cancer was significantly associated with HLA class I antigen-positive tumors. In contrast, in patients whose tumors had lost their HLA class I antigen expression, aspirin use did not change the outcome.”

(JAMA Intern Med. Published online March 31, 2014. doi:10.1001/jamainternmed.2014.511. Available pre-embargo to the media at http://media.jamanetwork.com.)

 

Editor’s Note: Authors made conflict of interest disclosures. This work was supported by an unrestricted grant from the Sloos-Alandt family. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

  

Commentary: Aspirin as Adjuvant Therapy for Stage III Colon Cancer.

 

In a related commentary, Alfred I. Neugut, M.D., Ph.D., of Columbia University, New York, writes: “When one sees a patient newly diagnosed as having cancer, after finishing the initial discussion and treatment plan, it is almost inevitable that the patient or a family member will inquire, “What else should he [or she] do?”

 

“For my own patients, I have so far not recommended aspirin [for colon cancer]. But I think based on current evidence, that if I personally had a stage III tumor, I would add aspirin to my FOLFOX (folinic acid-flourouracil-oxaliplatin) adjuvant therapy. And if I feel that way for myself, should I not convey that to my patients?” Neugut continues.

 

“But for now, as far as I am concerned, when a patient or a patient’s spouse asks, “What else should he be doing, Doctor?” – I will have a ready response,” Neugut concludes.

(JAMA Intern Med. Published online March 31, 2014. doi:10.1001/jamainternmed.2013.14544. Available pre-embargo to the media at http://media.jamanetwork.com.)

 

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.